Enhanced activity of apramycin and apramycin-based combinations against Mycobacteroides abscessus
Journal of Antimicrobial Chemotherapy · 2026
DOI: 10.1093/jac/dkaf433 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Yanqin Huang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, USA. Hauptthemen laut MEDLINE: Nebramycin, Mycobacterium abscessus, Anti-Bacterial Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Paul E. Strandjord Young Investigator Research Grant, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Background
Mycobacteroides abscessus is a rapidly growing non-tuberculous mycobacterium that causes chronic lung and soft tissue infections. Treatment options are severely limited. Amikacin has historically been a mainstay of combination treatment regimens. However, irreversible hearing loss and vestibular toxicity have led to a search for alternative agents. Apramycin is a novel aminoglycoside currently in Phase I clinical trials that may offer lower potential for ototoxic and renal toxic side effects.
Objectives
The goal of this study was to compare apramycin's in vitro activity with amikacin and other aminoglycosides against a large collection of M. abscessus clinical isolates, alone, and for apramycin and amikacin, in combination with clofazimine or linezolid. We also examined activity against a more limited collection of other rapidly growing mycobacteria.
Methods
Analysis was performed using reference broth microdilution MIC testing, inkjet printer-assisted checkerboard assays, and time–kill assays.
Results
Against M. abscessus, the MIC50/90 for apramycin (2 mg/L) was one-eighth that of amikacin (16 mg/L). Plazomicin was inactive, and organisms were rarely susceptible to tobramycin. Synergy of either apramycin or amikacin with clofazimine or linezolid was not detected by checkerboard assay. In time–kill studies, clofazimine modestly increased activity of apramycin and, to a lesser extent, amikacin. Apramycin and amikacin showed delayed bacterial killing that either achieved or approached a bactericidal threshold. Apramycin was similarly potent against other rapidly growing mycobacteria tested.
Conclusions
Apramycin exhibits more potent in vitro activity against a diverse set of M. abscessus and other rapidly growing mycobacteria than currently recommended aminoglycosides.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
- Harvard Medical School, Boston, MA, USA.
- Department of Chemistry, Northeastern University, Boston, MA 02115, USA.
Förderung
- NIAID NIH HHS
- Paul E. Strandjord Young Investigator Research Grant
- National Institute of Allergy and Infectious Diseases
- Massachusetts Life Science Center
- Academy of Clinical Laboratory Physicians and Scientists
Zitieren
APA
Huang, Y., Truelson, K. A., Stewart, I. A., O'Doherty, G. A., & Kirby, J. E. (2026). Enhanced activity of apramycin and apramycin-based combinations against Mycobacteroides abscessus. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf433
Vancouver
Huang Y, Truelson KA, Stewart IA, O'Doherty GA, Kirby JE. Enhanced activity of apramycin and apramycin-based combinations against Mycobacteroides abscessus. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkaf433
BibTeX
@article{Huang2026,
author = {Huang, Yanqin and Truelson, Katherine A and Stewart, Isabella A and O'Doherty, George A and Kirby, James E},
title = {Enhanced activity of apramycin and apramycin-based combinations against Mycobacteroides abscessus},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
doi = {10.1093/jac/dkaf433}
}
EUVIMED